AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00041470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 mcg/kg daily including the day of IV chemotherapy. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
Study NCT01453491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRT2104
Description: SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 25mg or 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule. All subjects will be provided with one dosing bottle per day that contains two 25 mg or 250 mg SRT2104 capsules for oral ingestion.
Study NCT03930589 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic conditioning
Description: BP cuff inflation for 5 min and deflation for 5 mins with 4 cycles
Study NCT03930589 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study NCT04791293 — intervention group
Intervention type: OTHER
Intervention: MELD-Na score
Description: MELD-Na scores will be compared between the groups
Study NCT02573571 — intervention group
Intervention type: OTHER
Intervention: Development of biomarkers
Description: Blood sampling
Study NCT00754689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimonabant
Description: Tablet, oral administration
Study NCT00754689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration
Study NCT00754689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Tablet, oral administration
Study NCT02951897 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: lobectomy
Study NCT02951897 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lobectomy
Study NCT01449123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol challenge test & reversibility test
Description: Patients perform an asthma control test (ACT) to establish if they are well controlled or symptomatic. All patients will perform then perform the mannitol challenge test. Aridol™ is an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness
Study NCT00754689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet, oral administration
Study NCT00754689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Tablet, oral administration
Study NCT03782064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells.
Study NCT03676010 — intervention group
Intervention type: OTHER
Intervention: Renal cell carcinoma
Description: No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
Study NCT03676010 — intervention group
Intervention type: OTHER
Intervention: Colon cancer
Description: No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy (adjuvant setting).
Study NCT03782064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC/myeloma fusions/GM-CSF
Description: The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.
Study NCT01697566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.
Study NCT01697566 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.
Study NCT03182283 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Person-centered psychosis care
Description: Person-centered care educational intervention for staff with following implementation of person-centered care in the clinic
Study NCT02099084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teduglutide
Description: Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.
Study NCT02099084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.
Study NCT02099084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching study drug, administered subcutaneously.
Study NCT02099084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching study drug, administered subcutaneously.
Study NCT02753478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intracoronary infusion with saline on 22 and 4°C
Description: Routine primary percutaneous intervention will be commenced. Patient will be asked to participate in the study.~Before reperfusion, saline on room temperature will be infused though the occlusion in the infarct related artery using an over the wire balloon catheter during 10 minutes. The balloon will be inflated to prevent reperfusion in that phase. After 10 minutes the balloon will be deflated allowing reperfusion and infusion with saline on 4°C will be continued for 10 minutes. After this, a coronary stent will be placed.
Study NCT03271164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FBPM10 System
Description: Application of the FBPM10 membrane followed by illumination with a multi-Light Emitting Diode (LED) lamp.
Study NCT03271164 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massages with vitamin E cream
Description: The other breast will be treated with wound massages with vitamin E cream.
Study NCT02164344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: probiotics (Streptococcus salivarius ssp. termophilus, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus faecium)
Study NCT04464811 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Furosemide stress test
Description: Furosemide stress test is performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have never received oral furosemide.
Study NCT04830943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Cerebrolysin will be prescribed in a dose of 5 ml ampoule once daily through intramuscular injection (1ml contains 215.2 mg cerebrolysin) for five times per week, for a total of 40 treatments (for 8 weeks), after which the cycle was individually repeated according to the response of the patient to therapy for a maximum of 24 weeks
Study NCT05211193 — intervention group
Intervention type: DEVICE
Intervention: eTNM delivered by URIS I nerve stimulation device
Description: eTNM delivered by URIS I nerve stimulation device, self administered in the subject's home for 30 minutes per day, for a minimum of 34 therapy session between day 1-42.
Study NCT03107728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advanced orthotic brace
Description: Participants will use an advanced exoskeletal orthosis.
Study NCT03107728 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional orthotic brace
Description: Participants will use the standard of care orthosis
Study NCT00243191 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: imatinib mesylate
Description: 400 mg orally twice a day for 10 - 14 days
Study NCT02558062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC ONE administration
Description: BAC ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and Cellvizio viewer software will be used to detect BAC ONE signal in the distal lung.
Study NCT02214069 — intervention group
Intervention type: DEVICE
Intervention: Record and transmit heart rhythm
Description: The patient uses the AliveCor device to record and transmit heart rhythm two times a day. The patient, device software, and Electrophysiologist interpret the rhythm
Study NCT02524145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Handgrip
Description: Subjects will perform static handgrip at 40% of maximum voluntary contraction until fatigue.
Study NCT02524145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Handgrip
Description: Subjects will perform static handgrip at 40% of maximum voluntary contraction until fatigue.
Study NCT02524145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
Study NCT02524145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
Study NCT02524145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
Study NCT02524145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
Study NCT02524145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Description: Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
Study NCT02524145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoproterenol
Description: Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
Study NCT02014662 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Eccentric exercise
Description: Each subject will perform eccentric exercise against a predefined personal maximal strength of their non-dominant leg on day 1. Changes on strength, biomarker concentrations and muscle protein synthesis during damage and recovery will be measured over 22 days.
Study NCT00693069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: clopidogrel 300 mg on the day prior to angiography
Study NCT00693069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: clopidogrel 600 mg on the day prior to angiography
Study NCT00693069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: clopidogrel 300 mg followed by 75 mg daily started one week prior to angiography
Study NCT00693069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: clopidogrel 300 mg followed by 150 mg daily started one week prior to angiography
Study NCT03388762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GlucoSupreme™ Herbal
Description: This study will assess changes in glycemic parameters and other biomarkers over a twelve week period, with two blood draws (Baseline and 12 weeks). Additionally, an IRB-approved research associate will call each study participant at the 6-week mid-point of the study to assess compliance and collect data on any adverse events.
Study NCT03388762 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.
Study NCT02993627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina
Description: 2 g(4\* 500 mg tablets) daily intake of Spirulina Platensis
Study NCT02993627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet therapy
Description: low calorie diet (-500 or -300 kcal) composed of 55% carbohydrate, 15% protein and 30% fat
Study NCT02993627 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: diet therapy
Description: low calorie diet (-500 or -300 kcal) composed of 55% carbohydrate, 15% protein and 30% fat
Study NCT03011112 — intervention group
Intervention type: PROCEDURE
Intervention: Observational procedure
Description: All the patients will undergo a standard observational procedure: i) diagnosed with KOA; ii) take a radiographic examination (x-ray); iii) assessed by WOMAC; iv) take an physical examination to avoid other disease; iv) take a gait examination on a treadmill in barefoot.
Study NCT03676010 — intervention group
Intervention type: OTHER
Intervention: Solid tumours undergoing image-guided tumor ablation
Description: No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
Study NCT01634724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a drug withdrawal during the long protocol
Description: GnRHa (triptorelin,0.05mg/d) was injected stimulously with FSH before dominant follicles were ≥ 14 mm. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (triptorelin,0.05mg/d) was withheld in the study group.
Study NCT02974829 — intervention group
Intervention type: OTHER
Intervention: follow-up
Study NCT03774797 — intervention group
Intervention type: OTHER
Intervention: Implementation Toolkit
Description: Post-implementation patients and providers will be assessed after the implementation toolkit has been used to improve service delivery at the study site.
Study NCT03971162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3+PRN
Description: intravitreal injection of Conbercept 0.5mg every month repeated for 3 months,
Study NCT03971162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6+PRN
Description: intravitreal injection of Conbercept 0.5mg every month repeated for 6 months
Study NCT02286596 — intervention group
Intervention type: DEVICE
Intervention: heparin-induced extracorporeal LDL precipitation
Description: Lipid apheresis for 3 hours
Study NCT02317497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Care Sedation (depth, level)
Description: As far as sedation is concerned, this will be adapted to all patients before randomization in the first 3 days according to what the diagnosis and acute treatment of the underlying disease demands. This will be deep sedation or even general anesthesia (for operative procedures) in most cases. After 72h at the sedation level of the respective randomization result, both groups will tried to be weaned from sedation with the goal of awakening, weaning from ventilation, overall de-escalation and transfer to rehabilitation as far as the course of the disease and the occurrence of complications allows. This reduction of sedation will follow individual regimes at he discretion of the treating physician. However, if cessation of sedation violates safety-limits (see below, Tab. 2) or is not feasible for other reasons, return to the level the patient was initially randomized for (or even below that) is mandatory with a re-assessment of safety for sedation weaning after 12h aimed for.
Study NCT02317497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Care Sedation (depth, level)
Description: As far as sedation is concerned, this will be adapted to all patients before randomization in the first 3 days according to what the diagnosis and acute treatment of the underlying disease demands. This will be deep sedation or even general anesthesia (for operative procedures) in most cases. After 72h at the sedation level of the respective randomization result, both groups will tried to be weaned from sedation with the goal of awakening, weaning from ventilation, overall de-escalation and transfer to rehabilitation as far as the course of the disease and the occurrence of complications allows. This reduction of sedation will follow individual regimes at he discretion of the treating physician. However, if cessation of sedation violates safety-limits (see below, Tab. 2) or is not feasible for other reasons, return to the level the patient was initially randomized for (or even below that) is mandatory with a re-assessment of safety for sedation weaning after 12h aimed for.
Study NCT02317497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressors to maintain normal blood pressure values, if needed
Study NCT02317497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressors to maintain normal blood pressure values, if needed
Study NCT02317497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osmotherapeutics to lowr intracranial pressure, if needed
Study NCT02317497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osmotherapeutics to lowr intracranial pressure, if needed
Study NCT02317497 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular stroke care to treat brain vessel occlusions, if needed
Study NCT02951897 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: segmentecomy
Study NCT02951897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy（pemetrexed+CISPLATIN）
Study NCT02951897 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lymphadenectomy
Description: Lymphadenectomy or lymph node dissection is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.
Study NCT02951897 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphadenectomy
Description: Lymphadenectomy or lymph node dissection is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.
Study NCT00505934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose within the following dose range, calculated on the basis of their age and weight:.~* Ages ≥ 1 month to \< 6 months: 14 mg/kg/day (7 mg/kg twice daily) to 42 mg/kg/day (21 mg/kg/day twice daily);~* Ages ≥ 6 months to \< 4 years: 20 mg/kg/day (10 mg/kg twice daily) to 60 mg/kg/day (30 mg/kg/day twice daily).~For subjects not taking levetiracetam oral solution prior to entering the study, the intravenous (IV) dosage corresponded to their age and weight as follows:~* Ages ≥ 1 month to \< 6 months: 14 mg/kg/day (7 mg/kg twice daily).~* Ages ≥ 6 months to \< 4 years: 20 mg/kg/day (10 mg/kg twice daily).
Study NCT02317497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular stroke care to treat brain vessel occlusions, if needed